Kaye Edward M. MD

Dr. Kaye Edward M.'s Form 4 filings reveal a pronounced sell-side bias, with no open-market purchases recorded across his 52 transactions. The overwhelming majority of his realized value—$7.79 million in total sales—has come from dispositions in two clinical-stage biopharmaceutical companies, Cytokinetics (CYTK) and Stoke Therapeutics (STOK). His most recent activity, concentrated in late 2025 and mid-2026, shows a consistent pattern of share sales following option exercises, particularly in STOK. For instance, on December 8, 2025, he executed three separate sales totaling approximately $433,385, following a pair of transactions on December 5 that brought in roughly $267,761, and earlier sales on December 4 worth about $199,198. These were preceded by option exercises on December 3, 2025, which generated no cash value but provided the shares sold. The sell pressure has continued into 2026, with a notable CYTK sale on June 1, 2026, valued at $223,172. However, this is balanced against recurring equity grants—coded as "A" for awards—that have added shares without cash outlay. These grants, such as the $12,476 award on July 15, 2026, and similar quarterly awards in April and January, suggest a compensation structure that periodically replenishes his holdings. The only other transaction type in his recent history is a series of "D" codes—sales back to the issuer—all dated February 27, 2026, in a third ticker, RNAM, though these were recorded at zero value, indicating either nominal pricing or a non-cash event. Overall, the data paints a picture of a director or officer who is systematically monetizing equity compensation rather than accumulating additional shares. The absence of any "P" (purchase) codes across his entire filing history underscores that his activity is entirely reactive to grants and option exercises, with the directional flow heavily favoring sales. While the dollar values are substantial, they are consistent with a routine liquidation strategy rather than a concentrated bet against any single company, as the sales are spread across multiple dates and two primary tickers.